Ronawk develops a T-Block technology producing patient-specific biologics to treat diseases, cancer, organ injuries, and burns.
Ronawk has raised $6.5M in total funding. The most recent round was Series A. The last funding was announced in May 2023.
Ronawk's investors include MassChallenge, Accelerate Venture Partners.
Ronawk is headquartered in Olathe, United States.
Ronawk develops a T-Block technology producing patient-specific biologics to treat diseases, cancer, organ injuries, and burns.
Ronawk is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ronawk — Funding & Investors." VCBacked, May 9, 2023, https://www.vcbacked.co/company/ronawk. Accessed July 19, 2026.
VCBacked. (2023). Ronawk — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/ronawk
{{cite web |title=Ronawk — Funding & Investors |url=https://www.vcbacked.co/company/ronawk |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated